Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 167

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 167
---
3,321 |
| Additional share of profit paid by Regeneron towards development costs(a)                |    833 |    668 |
| Reimbursement to Regeneron of selling expenses incurred                                  |   -637 |   -543 |
| Total: Monoclonal Antibody Alliance                                                      | -3,947 | -3,196 |
| Other (mainly Zaltrap and Libtayo)                                                       |    158 |    217 |
| Other operating income/(expenses), net related to Regeneron Alliance                     | -3,789 | -2,979 |
| of which amount presented in “Other operating income”                                    |    166 |    227 |

(a) As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to € 1.6 billion , compared with € 2.1 billion as of December 31, 2023 (see Note D.21.to our consolidated financial statements). 6/ Amortization of intangible assets Amortization charged against intangible assets amounted to € 1,749 million in 2024 , compared with € 1,911 million in 2023 . This reduction was mainly driven by the impact of some intangible assets reaching the end of their amortization periods. 7/ Impairment of intangible assets, net of reversals The monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of € 248 million in 2024 , comprising (i) an impairment loss of €640 million in connection with various research and development projects - including a €239 million loss resulting from the discontinuation in February 2025 of a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal totalling € 392 million recognized in connection with the divestment of the ProXTen technology platform and of Enjaymo, a commercialized product, certain assets within which had been subject to impairment losses in previous years. For 2023 , this line shows a net loss of € 896 million, mainly comprising an impairment loss of €833 million reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. 8/ Fair value remeasurement of contingent consideration Fair value remeasurements of contingent consideration assets and